HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
BO-0742
a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors
Networked:
1
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
3-Ring Heterocyclic Compounds
Acridines: 325
BO-0742: 1
Organic Chemicals: 133
Amines: 4871
Aniline Compounds: 46
BO-0742: 1
Experts
1.
Chou, Ting-Chao
: 1 article (04/2009)
2.
Lee, Chien-Hsin
: 1 article (04/2009)
3.
Shao, Li-En
: 1 article (04/2009)
4.
Su, Tsann-Long
: 1 article (04/2009)
5.
Yu, Alice L
: 1 article (04/2009)
6.
Yu, John
: 1 article (04/2009)
Related Diseases
1.
Neoplasms (Cancer)
04/18/2009 - "
This is a preclinical study of BO-0742, a derivative of 3-(9-acridinylamino)-5-hydroxymethyl-aniline (AHMA) and N-mustard, as an anti-cancer agent.
"
04/18/2009 - "
Thus, BO-0742 is a potent anti-cancer agent worthy of further clinical development.
"
04/18/2009 - "
BO-0742, a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors.
"
04/18/2009 - "
MTS assays revealed a broad spectrum of anti-cancer activities in vitro, with the greatest cytotoxicity against leukemia and neuroblastoma including those with drug resistant characteristics, and a good therapeutic index with leukemia being 10-40 times more sensitive to BO-0742 than hematopoietic progenitors.
"
2.
Ovarian Neoplasms (Ovarian Cancer)
04/18/2009 - "
Administration of BO-0742 at an optimal dose schedule based on its pharmacokinetics significantly suppressed the growth of xenografts of human breast and ovarian cancers in mice.
"
3.
Neuroblastoma
04/18/2009 - "
MTS assays revealed a broad spectrum of anti-cancer activities in vitro, with the greatest cytotoxicity against leukemia and neuroblastoma including those with drug resistant characteristics, and a good therapeutic index with leukemia being 10-40 times more sensitive to BO-0742 than hematopoietic progenitors.
"
4.
Leukemia
04/18/2009 - "
BO-0742, a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors.
"
04/18/2009 - "
MTS assays revealed a broad spectrum of anti-cancer activities in vitro, with the greatest cytotoxicity against leukemia and neuroblastoma including those with drug resistant characteristics, and a good therapeutic index with leukemia being 10-40 times more sensitive to BO-0742 than hematopoietic progenitors.
"